It was illustrated that EGCG possessed the therapeutic potential against Alzheimer's disease, and had been recognized as an antiamyloid agent.35, 36 In addition, EGCG inhibited the aggregation of tau into toxic oligomers, and protected the neuronal model cells.37 Furthermore, we also found that EGCG could firmly bind to HMGB1 near Cys-106, and subsequently stimulated large HMGB1 conformational change.38 All these indicted that EGCG possessed unique functions, which determined its diverse applications in biomedical field. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.